Literature DB >> 15315313

Free to total PSA ratio is not a reliable predictor of prostate biopsy outcome.

Stefano Ciatto1, Tiziana Rubeca, Massimo Confortini, Giovanni Pontenani, Claudio Lombardi, Paola Zendron, Simonetta Di Lollo, Emanuele Crocetti.   

Abstract

AIMS AND
BACKGROUND: The aim of this study was to assess the validity of predictors of prostate biopsy outcome in order to improve their positive predictive value.
MATERIAL AND METHODS: The study material consisted of a consecutive series of 410 prostate biopsies performed during 2003. The variables tested as possible predictors were age, findings at palpation (DRE) and ultrasonography (TRUS), total prostate-specific antigen (PSA), and free-to-total prostate-specific antigen (F/T) ratio. The association with biopsy outcome (cancer vs non-cancer) was investigated by univariate and multivariate analysis.
RESULTS: All tested variables showed a statistically significant and independent association with biopsy outcome both in univariate and multivariate analysis. Nevertheless, no variable had good performance as a biopsy indicator: depending on the considered variable, three to nine cancer biopsies would be delayed in order to avoid ten benign biopsies. Using 0.12, 0.15 and 0.20 as the cutoff for F/T would avoid 77.3%, 64.4% and 43.1% of benign biopsies but would delay 54.0%, 35.6% and 21.0% of cancer biopsies, respectively.
CONCLUSION: Although it may contribute to diagnostic suspicion, F/T should never exclude a biopsy indicated because of suspicion arising from other diagnostic tests.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315313     DOI: 10.1177/030089160409000311

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

Review 1.  A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.

Authors:  Bradley King; Jana McHugh; Katie Snape
Journal:  Appl Clin Genet       Date:  2021-05-20

Review 2.  A systematic review of the diagnostic accuracy of prostate specific antigen.

Authors:  Philip Harvey; Amman Basuita; Deborah Endersby; Ben Curtis; Aphrodite Iacovidou; Mary Walker
Journal:  BMC Urol       Date:  2009-09-10       Impact factor: 2.264

Review 3.  Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.

Authors:  Jana McHugh; Edward J Saunders; Tokhir Dadaev; Eva McGrowder; Elizabeth Bancroft; Zsofia Kote-Jarai; Rosalind Eeles
Journal:  Br J Cancer       Date:  2021-12-18       Impact factor: 9.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.